ClinicalTrials.gg
Active, not recruitingNCT04626635COMBINE-EGFR-1Updated Jul 2, 2026

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

A Phase 1/2 interventional study of REGN7075 and Cemiplimab in Advanced Solid Tumors, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 54 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
548
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage.

The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients.

The study is also looking at:

  • Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy
  • How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy
  • How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy
  • To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor
  • Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Variety of mixed advanced solid tumor types
  • First in Human (FIH)
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has an (ECOG) performance status of 0 or 1
  2. Has or cytologically confirmed cancer that meets criteria as defined in the protocol
  3. Expansion Cohorts only: Is anti-Programmed cell Death protein-1 ()/Programmed cell Death Ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1
  4. Has at least 1 lesion that meets study criteria as defined in the protocol
  5. Willing to provide tumor tissue from newly obtained (at a minimum core biopsy) from a tumor site that has not been previously irradiated
  6. Has adequate organ and bone marrow function as defined in the protocol
  7. In the judgement of the investigator, has a of at least 3 months

Key Exclusion Criteria:

  1. Is currently participating in another study of a therapeutic agent
  2. Has participated in any study of an agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol
  3. Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities
  4. Has received recent anti-Epidermal Growth Factor Receptor (EGFR) antibody therapy as defined in the protocol
  5. Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events
  6. Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug.
  7. Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol
  8. Has second that is progressing or requires active treatment as defined in the protocol
  9. Has any condition requiring ongoing/continuous therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol
  10. Has ongoing or recent (within 5 years) evidence of significant disease or any other condition that required treatment with systemic treatments as defined in the protocol
  11. Has untreated or active primary brain tumor, Central Nervous System (CNS) , , or spinal cord compression
  12. Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug
  13. Has any ongoing inflammatory skin disease as defined in the protocol

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
548 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Variety of mixed advanced solid tumor types

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion A

    Triple Negative Breast Cancer (TNBC)

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion B

    Cutaneous Squamous Cell Carcinoma (CSCC)

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion C

    Non-Small Cell Lung Cancer (NSCLC)

    Drug: REGN7075 · Drug: Cemiplimab · Drug: Platinum-based doublet chemotherapy

  • Experimental
    Dose Expansion D

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion E

    Microsatellite Stable-Colorectal Cancer (MSS-CRC), with Active Liver Metastases and/or Active Peritoneal Metastases

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion F

    MSS-CRC with Isolated Lung/Lymph Node Metastases (no active liver and no active peritoneal metastases)

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion G

    Epidermal Growth Factor Receptor (EGFR) -mutant NSCLC Post Third Generation tyrosine kinase inhibitor (TKI)

    Drug: REGN7075 · Drug: Cemiplimab · Drug: Platinum-based doublet chemotherapy

  • Experimental
    Dose Expansion H

    EGFR-mutant NSCLC Post Third Generation TKI and Post Platinum-Doublet Chemotherapy

    Drug: REGN7075 · Drug: Cemiplimab

  • Experimental
    Dose Expansion I

    Third-line (3L) MSS-CRC with Active Liver Metastases

    Drug: REGN7075 · Drug: Cemiplimab · Drug: Bevacizumab · Drug: Trifluridine-tipiracil

  • Experimental
    Dose Expansion J

    3L MSS-CRC without Active Liver Metastases

    Drug: REGN7075 · Drug: Cemiplimab · Drug: Bevacizumab · Drug: Trifluridine-tipiracil

Interventions

  • DrugREGN7075

    Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)

    Also known as: marlotamig

  • Administered concomitantly Q3W by IV infusion or SC injection

    Also known as: REGN2810, Libtayo

  • DrugPlatinum-based doublet chemotherapy

    Administered IV Q3W

  • Administered per protocol

  • DrugTrifluridine-tipiracil

    Administered per protocol

06

What researchers measure

Primary outcomes

  1. The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period

    Dose escalation

    Time frame: Up to 6 weeks

  2. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)

    Dose escalation

    Time frame: Approximately 90 days from last dose; up to 5 years

  3. Incidence and severity of Adverse Events of Special Interest (AESIs)

    Dose escalation

    Time frame: Approximately 90 days from last dose; up to 5 years

  4. Incidence and severity of Serious Adverse Events (SAEs)

    Dose escalation

    Time frame: Approximately 90 days from last dose; up to 5 years

  5. Incidence and severity of grade ≥3 laboratory abnormalities

    Dose escalation

    Time frame: Approximately 90 days from last dose; up to 5 years

  6. Objective Response Rate (ORR)

    Dose expansion

    Time frame: Up to 5 years

Secondary outcomes

  1. Concentrations of marlotamig in serum

    Dose escalation and dose expansion

    Time frame: Up to 5 years

  2. ORR

    Dose escalation

    Time frame: Up to 5 years

  3. Progression Free Survival (PFS)

    Dose escalation and dose expansion

    Time frame: Up to 5 years

  4. Duration of Response (DOR)

    Dose escalation and dose expansion

    Time frame: Up to 5 years

  5. Disease Control Rate (DCR)

    Dose escalation and dose expansion

    Time frame: Up to 5 years

  6. Complete Response (CR) rate

    Dose escalation and dose expansion

    Time frame: Up to 5 years

  7. Overall survival (OS)

    Dose escalation and dose expansion

    Time frame: Up to 5 years

  8. Incidence of Anti-Drug Antibodies (ADA) to marlotamig

    Dose escalation and dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  9. Magnitude of ADA to marlotamig

    Dose escalation and dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  10. Incidence of ADA to cemiplimab

    Dose escalation and dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  11. Magnitude of ADA to cemiplimab

    Dose escalation and dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  12. The incidence and severity of TEAEs

    Dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  13. The incidence and severity of AESIs

    Dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  14. The incidence and severity of SAEs

    Dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  15. The incidence and severity of grade ≥3 laboratory abnormalities

    Dose expansion

    Time frame: Approximately 90 days from last dose; up to 5 years

  16. Patient reported Quality of Life (QoL) per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: Approximately 90 days from last dose; up to 5 years

  17. Patient reported Quality of Life (QoL) per EORTC QLQ-CR29 in CRC patients

    The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.

    Time frame: Approximately 90 days from last dose; up to 5 years

  18. Patient reported Quality of Life (QoL) per EORTC QLQ-BR23 in breast cancer patients

    The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  19. Patient reported Quality of Life (QoL) per EORTC QLQ-LC13 in NSCLC patients

    The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".

    Time frame: Approximately 90 days from last dose; up to 5 years

  20. Patient reported Quality of Life (QoL) per EORTC QLQ-HN35 in HNSCC patients

    The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses. The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.

    Time frame: Approximately 90 days from last dose; up to 5 years

  21. Patient reported Quality of Life (QoL) per EQ-5D-5L

    The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  22. Patient reported symptoms per EORTC QLQ-C30

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: Approximately 90 days from last dose; up to 5 years

  23. Patient reported symptoms per EORTC QLQ-CR29 in CRC patients

    The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). . Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.

    Time frame: Approximately 90 days from last dose; up to 5 years

  24. Patient reported symptoms per EORTC QLQ-BR23 in breast cancer patients

    The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  25. Patient reported symptoms per EORTC QLQ-LC13 in NSCLC patients

    The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".

    Time frame: Approximately 90 days from last dose; up to 5 years

  26. Patient reported symptoms per EORTC QLQ-HN35 in HNSCC patients

    The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses. The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.

    Time frame: Approximately 90 days from last dose; up to 5 years

  27. Patient reported symptoms per EQ-5D-5L

    The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  28. Patient reported functioning per EORTC QLQ-C30

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: Approximately 90 days from last dose; up to 5 years

  29. Patient reported functioning per EORTC QLQ-CR29 in CRC patients

    The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.

    Time frame: Approximately 90 days from last dose; up to 5 years

  30. Patient reported functioning per EORTC QLQ-BR23 in breast cancer patients

    The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  31. Patient reported functioning per EORTC QLQ-LC13 in NSCLC patients

    The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".

    Time frame: Approximately 90 days from last dose; up to 5 years

  32. Patient reported functioning per EORTC QLQ-HN35 in HNSCC patients

    The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses. The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.

    Time frame: Approximately 90 days from last dose; up to 5 years

  33. Patient reported functioning per EQ-5D-5L

    The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  34. Patient reporting general health status per EORTC QLQ-C30

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: Approximately 90 days from last dose; up to 5 years

  35. Patient reporting general health status per EORTC QLQ-CR29 in CRC patients

    The EORTC QLQ CR-29 questionnaire consists of 29 items (Likert scale), with a response scale for each of them from 1 to 4, with the following structure: 1 = Not at All 2 = A little; 3 = Quite a Bit; 4 = Very much. The QLQ-CR29 has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items (urinary incontinence, dysuria, abdominal pain, buttock pain, bloating, dry mouth, hair loss, taste, anxiety, weight, flatulence, fecal incontinence, sore skin, embarrassment, stoma care problems, sexual interest (men), impotence, sexual interest (women), and dyspareunia). Scores can be linearly transformed to provide a score from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms on the symptom scales.

    Time frame: Approximately 90 days from last dose; up to 5 years

  36. Patient reporting general health status per EORTC QLQ-BR23 in breast cancer patients

    The EORTC-QLQ-BR23 includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions use 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale=high/healthy level of functioning. High score for single item=high level of symptomatology/problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

  37. Patient reporting general health status per EORTC QLQ-LC13 in NSCLC patients

    The EORTC QLQ-LC13 is a 13-item, disease-specific module which assesses quality of life across multiple scales, including dyspnea, cough and chest pain. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much".

    Time frame: Approximately 90 days from last dose; up to 5 years

  38. Patient reporting general health status per EORTC QLQ-HN35 in HNSCC patients

    The EORTC QLQ-HN35 is a 35-item, disease-specific module which assesses quality of life across multiple scales, including pain, swallowing, and senses. The questionnaire has 35 Likert type questions in total and the evaluation is made by giving the score of None: 1, A little: 2, Quite: 3, A lot: 4.

    Time frame: Approximately 90 days from last dose; up to 5 years

  39. Patient reporting general health status per EQ-5D-5L

    The EQ-5D-5L consists of EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: Approximately 90 days from last dose; up to 5 years

07

Study locations

54 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Nov 2026, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 12, 2020
StartActual
Dec 21, 2020
Primary completionEst.
Nov 13, 2026
CompletionEst.
Mar 5, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04626635
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Dec 21, 2020
Primary completion
Nov 13, 2026 (estimated)
Completion
Mar 5, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion